Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-19.23%
0%
-19.23%
6 Months
-13.7%
0%
-13.7%
1 Year
-1.56%
0%
-1.56%
2 Years
-20.25%
0%
-20.25%
3 Years
-1.56%
0%
-1.56%
4 Years
186.36%
0%
186.36%
5 Years
186.36%
0%
186.36%
Thiogenesis Therapeutics Corp. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0.00%
EBIT Growth (5y)
-34.21%
EBIT to Interest (avg)
-4.56
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
32.60
EV to EBIT
-5.84
EV to EBITDA
-5.84
EV to Capital Employed
-22.18
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-509.41%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-1.80
-0.70
-157.14%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-1.90
-0.70
-171.43%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -171.43% vs 22.22% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-3.60
-5.20
30.77%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-3.10
-5.10
39.22%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 39.22% vs -30.77% in Dec 2023
About Thiogenesis Therapeutics Corp. 
Thiogenesis Therapeutics Corp.
Finance
Rozdil Capital Corp. is a Canada-based capital pool company. The principal business of the Company is the identification and evaluation of assets or businesses with the intention of completing a qualifying transaction under relevant policies of the exchange. It has not commenced any operations and has no assets.






